Attention:

Certain features of Sigma-Aldrich.com will be down for maintenance the evening of Friday August 18th starting at 8:00 pm CDT until Saturday August 19th at 12:01 pm CDT.   Please note that you still have telephone and email access to our local offices. We apologize for any inconvenience.


Geodon ® (Ziprasidone): Discovery of a Novel Antipsychotic Drug


 email this page to a friendDr. John A. Lowe III
 Dr. John A. Lowe III
 Co-inventor of Geodon ® at Pfizer
 Winner of 2011 ACS Award in
 Industrial Chemistry
 JL3Pharma LLC

 

Watch Webinar Now!

Overview:
The first antipsychotic drugs, discovered serendipitously in clinical testing, provided a major advance in the treatment of mental disease. However, they were not without side effect liabilities, and this presented an opportunity to address an unmet medical need. Although there were many potential avenues to explore, we selected a combination of D2 dopamine and 5-HT2 serotonin receptor blockade, to ensure efficacy and reduce side effects, respectively. Our strategy led us to a series of oxindoles linked to benzisothiazolyl piperazine, from which we selected Ziprasidone as a novel atypical antipsychotic agent for clinical trials.

Ziprasidone’s favorable ratio of 5-HT2 to D2 receptor affinity affords antipsychotic efficacy with low side-effect propensity, including a weight neutral profile. Ziprasidone (marketed as Geodon ® in the U.S.) is a successful atypical antipsychotic drug that has benefited over one million patients.

Geodon ® (Ziprasidone):

Areas covered in the webinar:

  • History of antipsychotic drug discovery
  • Strategy for discovery of novel second generation antipsychotic drugs
  • Oxindole and benzisothiazole synthetic chemistry
  • SAR of ziprasidone and its analogues
  • Clinical results with ziprasidone